[-] Show simple item record

dc.contributor.authorLaVoy, Rachel E.eng
dc.contributor.authorHu, Peter T.eng
dc.contributor.authorRamasubbaiah, Rashmieng
dc.date.issued2012eng
dc.description.abstractThe chemotherapeutic agent cisplatin is usually contraindicated in renal transplant recipients due to its well-known side effect of nephrotoxicity, but is an important (and sometimes irreplaceable) drug in the management of cancer. We report a case of cisplatin usage concurrently with radiation (CRT) in unresectable head and neck cancer, along with a review of the literature.eng
dc.identifier.urihttp://hdl.handle.net/10355/16073
dc.languageEnglisheng
dc.relation.ispartofcommunityUniversity of Missouri--Columbia. Health Sciences Research Day.eng
dc.subjectkidney transplanteng
dc.subjectimmunosuppressioneng
dc.subjectsquamous cell cancereng
dc.subjectfirst line therapyeng
dc.subject.lcshCisplatineng
dc.subject.lcshKidneys -- Transplantationeng
dc.subject.lcshCancer -- Treatmenteng
dc.titleCisplatin in renal transplant recipients: not an absolute contraindicationeng
dc.typePostereng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record